RECCE PHARMACEUTICALS LTD — Director's Dealing 2020

Jul 13, 2020

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity	Recce Pharmaceuticals Ltd
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of DirectorDate of appointment	Dr. Alan Dunton
	14 July 2020

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil

• See chapter 19 for defined terms.

11/3/2002

Appendix 3X Page 1

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

Name of holder & nature ofinterestNote: Provide details of the circumstances giving rise tothe relevant interest.	Number & class of SecuritiesNil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Under the terms contained in Dr. Dunton’s letter ofappointment with Recce Pharmaceuticals Ltd, Dr.Dunton receives AUD$60,000 per annum (plusapplicable superannuation) and an allocation of fullypaid ordinary shares in the Company as remunerationfor his services. The issue of shares is subject toshareholder approval at the next Annual GeneralMeeting (AGM).
Nature of interest	Subject to shareholder approval being obtained at theAGM, Dr. Dunton will receive an allocation of 60,000fully paid ordinary shares as part of his remuneration forhis services.
Name of registered holder(if issued securities)	N/A
No. and class of securities towhich interest relates	60,000 fully paid ordinary shares (subject to shareholderapproval being obtained at the AGM).

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002